FDA Ortho Panel Says 'No' To Medtronic DIAM Spine Device
This article was originally published in The Gray Sheet
Minimally invasive interspinous spacer did not get the support of an FDA advisory panel in the face of serious questions about Medtronic's study design.
You may also be interested in...
Boston Scientific Buys Vertiflex For $465M To Add Minimally Invasive Lumbar Procedure
Vertiflex sells the Superion indirect decompression system, a minimally invasive device to treat lumbar spinal stenosis. Boston Scientific expects it to bring in $60m in revenue in 2019 to its Neuromodulation business.
In Case You Missed It: Top 10 Gray Sheet Stories In February
Our coverage of the highly anticipated release of the revised ISO 13485 international medical device quality systems standard attracted the most attention from Gray Sheet readers last month. Also popular: stories about FDA photography during facility inspections, European postmarket surveillance reforms, and policy updates focused on human factors.
Ortho Panel Green Lights VertiFlex’s Superion Spine Spacer
A majority of FDA advisors say the device intended to treat lumbar spinal stenosis has a positive risk-benefit profile but should require an extended postmarket trial to evaluate its safety and efficacy over a longer time period.